The acute lymphoblastic leukemia (ALL) therapy market is growing steadily, fueled by innovations in the treatment paradigm. The availability of premium-priced branded agents prescribed in multidrug…
EPI Data Slicer
Acute lymphoblastic leukemia (ALL) is the most common childhood malignancy and accounts for about 20% of cases of acute leukemia in adults. Chemotherapy has remained the backbone of first-line…
Clarivate Epidemiology’s coverage of acute lymphoblastic leukemia (ALL) comprises epidemiological estimates of key patient populations in 45 countries worldwide. We report both the incidence and…
Clarivate’s extended worldwide coverage is the first and only evidence-based data set of epidemiological forecasts for key acute lymphoblastic leukemia populations covering 171 countries and…
Acute lymphoblastic leukemia (ALL) is a cancer of the white blood cells. Over the last few years, a number of agents have been launched that have improved treatment outcomes for patients with ALL,…
Acute lymphoblastic leukemia (ALL) is a cancer of the white blood cells. Over the last few years, a number of agents have been launched that have improved treatment outcomes for patients with ALL…
Acute lymphoblastic leukemia (ALL), also known as acute lymphoid leukemia or cancer of the white blood cells, develops from lymphocytes overproduced in the bone marrow that spread to other sites…